Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma

被引：0

作者：

Akula, Vinita ^{[1
]}

Chen, Lily ^{[1
]}

Acikgoz, Yusuf ^{[2
]}

Klein, Katherine ^{[1
]}

Yavuz, Betul Gok ^{[3
]}

Cevik, Lokman ^{[4
]}

Demir, Tarik ^{[5
]}

Manne, Ashish ^{[2
]}

Sahin, Ilyas ^{[6
]}

Kaseb, Ahmed ^{[7
]}

Hasanov, Elshad ^{[2
]}

机构：

[1] Univ Texas, Dept Internal Med, Hlth Sci Ctr, Houston UTHealth, Houston, TX USA

[2] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA

[3] Univ Missouri, Dept Med, Columbia, MO USA

[4] Ohio State Univ, Wexner Med Ctr, Dept Pathol, Columbus, OH USA

[5] Northwestern Univ, Div Hematol & Oncol Dev Therapeut Inst, Chicago, IL USA

[6] Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL USA

[7] Univ Texas, Dept Gastrointestinal Med Oncol, MD Anderson Canc Ctr, Houston, TX USA

来源：

NPJ PRECISION ONCOLOGY | 2025年 / 9卷 / 01期

关键词：

CAMRELIZUMAB PLUS APATINIB; OPEN-LABEL; DOUBLE-BLIND; SINGLE-ARM; RECURRENCE; RESECTION; SORAFENIB; CANCER; TRIAL; HCC;

D O I：

10.1038/s41698-025-00846-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC treatment is challenging; surgical resection is the primary curative treatment for early-stage disease, but recurrence rates are high. Immune checkpoint inhibitors (ICIs) are a promising neoadjuvant treatment that can reduce recurrence rates and mortality after surgery and achieve complete/partial responses. Clinical trials provide strong evidence for the efficacy and safety of ICI monotherapy for neoadjuvant HCC treatment.

引用

页数：13

共 50 条

[31] Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma
Chen, Xiu
Kou, Liqiu
Xie, Xiaolu
Su, Song
Li, Jun
Li, Yaling
IMMUNOLOGY, 2024, 172 (01) : 21 - 45
[32] Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Sangro, Bruno
Chan, Stephen L.
Meyer, Tim
Reig, Maria
El-Khoueiry, Anthony
Galle, Peter R.
JOURNAL OF HEPATOLOGY, 2020, 72 (02) : 320 - 341
[33] Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma
Muhammed, Ambreen
D'Alessio, Antonio
Enica, Andrei
Talbot, Thomas
Fulgenzi, Claudia Angela Maria
Nteliopoulos, Georgios
Goldin, Robert D.
Cortellini, Alessio
Pinato, David J.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2022, 22 (03) : 253 - 264
[34] The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
Leone, Patrizia
Solimando, Antonio Giovanni
Fasano, Rossella
Argentiero, Antonella
Malerba, Eleonora
Buonavoglia, Alessio
Lupo, Luigi Giovanni
De Re, Valli
Silvestris, Nicola
Racanelli, Vito
VACCINES, 2021, 9 (05)
[35] The quest for precision oncology with immune checkpoint inhibitors for hepatocellular carcinoma
Cabibbo, Giuseppe
Singal, Amit G.
JOURNAL OF HEPATOLOGY, 2022, 76 (02) : 262 - 264
[36] Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Cheng, Ann-Lii
Hsu, Chiun
Chan, Stephen L.
Choo, Su-Pin
Kudo, Masatoshi
JOURNAL OF HEPATOLOGY, 2020, 72 (02) : 307 - 319
[37] Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma
Rizzo, Alessandro
Ricci, Angela Dalia
Brandi, Giovanni
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2022, 7 (01): : 1 - 3
[38] The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma
Kim, Beom Kyung
GUT AND LIVER, 2024, 18 (01) : 3 - 4
[39] Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors
Rujia Zhang
Haoran Zhao
Peng Wang
Zuoming Guo
Chunxun Liu
Zhaowei Qu
BMC Cancer, 23
[40] Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
Pinter, Matthias
Scheiner, Bernhard
Pinato, David J.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (08): : 760 - 770

← 1 2 3 4 5 →